Soru

Zorluk: ZorInfectious Diseases

A 64-year-old female patient is currently hospitalized for the treatment of acute pyelonephritis. She initially presented to the emergency department three days ago with severe right-sided flank pain, dysuria, and a temperature of 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}). Blood cultures were drawn, and empiric intravenous ceftriaxone was initiated. The admission blood cultures show no growth to date. However, the urine culture obtained prior to antibiotic administration has grown >105>10^5 colony-forming units/mL of *Escherichia coli*. The susceptibility report is as follows:

Antimicrobial AgentResult
AmoxicillinResistant
CefazolinResistant
CeftriaxoneResistant
CefepimeResistant
CiprofloxacinResistant
ErtapenemSusceptible
MeropenemSusceptible
NitrofurantoinSusceptible
Trimethoprim-sulfamethoxazoleSusceptible

Today, the patient reports that her flank pain has nearly resolved. Her current temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 122/78 mmHg122/78 \text{ mmHg}, and heart rate is 78/min78/\text{min}. She is tolerating a regular diet without nausea.

Based on the culture results and the patient's clinical progress, which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Transition to oral trimethoprim-sulfamethoxazoleCevap
  2. B
    Transition to oral nitrofurantoin
  3. C
    Transition to intravenous ertapenem
  4. D
    Transition to intravenous meropenem
  5. E
    Continue intravenous ceftriaxone

Cevap

Transition to oral trimethoprim-sulfamethoxazole
The correct response identifies that this patient has acute pyelonephritis caused by an Extended-Spectrum Beta-Lactamase (ESBL)-producing strain of E. coli, evidenced by resistance to ceftriaxone and cefepime. Because the patient is now afebrile, hemodynamically stable, and able to tolerate an oral diet, she is an excellent candidate for step-down therapy from intravenous to oral antibiotics. This transition minimizes hospital length of stay and reduces the risks associated with intravenous catheters. Trimethoprim-sulfamethoxazole is the optimal choice; the isolate is highly susceptible, and the medication achieves excellent concentrations in both the urine and the renal parenchyma.

Adım Adım Çözüm

1
Interpret the antibiotic susceptibility profile.
The E. coli isolate is resistant to third- and fourth-generation cephalosporins, indicating it is an Extended-Spectrum Beta-Lactamase (ESBL) producer.
Accurate identification of the resistance mechanism dictates which antibiotic classes can be safely used.
2
Assess the patient's current clinical stability.
The patient is afebrile, hemodynamically stable, and tolerating an oral diet.
Clinical stability determines whether the patient must remain on intravenous therapy or can be transitioned to an oral regimen.
3
Select the appropriate targeted oral agent based on pharmacokinetics.
Trimethoprim-sulfamethoxazole is selected because it is susceptible and penetrates renal tissue, whereas nitrofurantoin does not.
Pyelonephritis requires antibiotics that achieve high tissue concentrations in the kidneys, not just the lower urinary tract.

Anahtar Kavram

Management of acute pyelonephritis caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing Enterobacteriaceae involves transitioning clinically stable patients to highly bioavailable oral antibiotics with adequate renal tissue penetration, such as trimethoprim-sulfamethoxazole, to promote antibiotic stewardship and avoid unnecessary intravenous carbapenem use.
Tahmini Süre:1m 30s
Bu soruyu puanla